Volume : II, Issue : VII, July - 2013

Evalution and Impact of Anti–Tuberculosis Drug : A Review

H. K. Garg, Ashish Shrivastava

Abstract :

Since the time of discovery of Mycobacterium tuberculosis as an agent causing tuberculosis , permanent eradication of this disease has been a cause of concern. Although a large number of drugs exit for the treatment of tuberculosis, 1.7 million people still die every year from this infection. Isoniazid and rifampin are effective anti-tuberculosis drugs only for the standard treatment of TB. Multidrug-resistant tuberculosis bacillus developed resistance against isoniazid and rifampin, therefore complicated problems came forward in treatment of MDR-TB due to which second line anti-tuberculosis drug like fluoroquinolone has invented. Recently an extensively drug-resistant (XDR) strain of M.tuberculosis had observed which has developed resistance against isoniazid, rifampin fluoroquinolone and an aminoglycoside. XDR-TB is the most severe form of tuberculosis, against which no effective drug has been registered till now. Although a new generation TBK-613 of fluoroquinolone is on medical trial for the treatment of this severe form of tuberculosis.

Keywords :

Article: Download PDF   DOI : 10.36106/ijsr  

Cite This Article:

H. K. Garg, Ashish Shrivastava Evalution and Impact of Anti-Tuberculosis Drug : A Review International Journal of Scientific Research, Vol : 2, Issue : 7 July 2013

Number of Downloads : 594

References :